ESPR

0.92

4.39% 0.0387

Vorhandelsmarkt: .94 0.02 +2.17%

Esperion Therapeutics Inc (ESPR)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ESPR? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$0.8813

Offen:

$0.8898

24-Stunden-Volumen:

4.84M

Relative Volume:

1.09

Marktkapitalisierung:

$174.30M

Einnahmen:

$116.33M

Nettoeinkommen (Verlust:

$-209.25M

KGV:

-0.434

EPS:

-2.12

Netto-Cashflow:

$-135.49M

1W Leistung:

-3.16%

1M Leistung:

-45.24%

6M Leistung:

-56.19%

1J Leistung:

-53.77%

1-Tages-Spanne:

$0.8519

$0.9389

1-Wochen-Bereich:

$0.8191

$1.06

52-Wochen-Spanne:

$0.8191

$3.94

Esperion Therapeutics Inc Stock (ESPR) Company Profile

Firmenname

Esperion Therapeutics Inc

Sektor

Healthcare (1155)

Branche

Drug Manufacturers - Specialty & Generic (1)

Telefon

734-887-3903

Adresse

3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI

Mitarbeiter

240

Twitter

@esperioninc

Nächster Verdiensttermin

2025-03-04

Neueste SEC-Einreichungen

ESPR's Discussions on Twitter

Vergleichen Sie ESPR mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ESPR Esperion Therapeutics Inc	0.92	174.30M	116.33M	-209.25M	-135.49M	-2.12
ZTS Zoetis Inc	153.47	65.50B	9.26B	2.49B	2.30B	5.47
TAK Takeda Pharmaceutical Co Adr	15.03	46.99B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	10.18	45.96B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	14.87	17.04B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	291.38	12.77B	2.76B	1.11B	898.10M	22.77

Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-12-18	Eingeleitet	Goldman	Neutral
2024-12-17	Eingeleitet	Cantor Fitzgerald	Overweight
2024-06-20	Herabstufung	BofA Securities	Neutral → Underperform
2024-01-03	Herabstufung	BofA Securities	Buy → Neutral
2023-11-20	Fortgesetzt	JP Morgan	Neutral
2023-08-01	Hochstufung	Northland Capital	Under Perform → Market Perform
2023-06-15	Hochstufung	BofA Securities	Underperform → Buy
2023-03-16	Herabstufung	BofA Securities	Neutral → Underperform
2023-03-16	Herabstufung	Northland Capital	Market Perform → Under Perform
2023-03-07	Hochstufung	Credit Suisse	Underperform → Neutral
2023-02-27	Fortgesetzt	BofA Securities	Neutral
2023-02-24	Hochstufung	Jefferies	Hold → Buy
2023-02-03	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2022-08-03	Herabstufung	Credit Suisse	Neutral → Underperform
2022-05-05	Hochstufung	JP Morgan	Underweight → Neutral
2022-03-10	Eingeleitet	H.C. Wainwright	Buy
2021-10-19	Herabstufung	Credit Suisse	Outperform → Neutral
2021-10-14	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2021-05-05	Herabstufung	Stifel	Buy → Hold
2021-04-26	Fortgesetzt	Credit Suisse	Outperform
2021-03-11	Eingeleitet	Morgan Stanley	Equal-Weight
2021-02-12	Herabstufung	Jefferies	Buy → Hold
2021-02-09	Herabstufung	Goldman	Neutral → Sell
2021-01-15	Herabstufung	BofA Securities	Buy → Neutral
2020-11-10	Hochstufung	Credit Suisse	Neutral → Outperform
2020-09-29	Fortgesetzt	JP Morgan	Underweight
2020-08-11	Herabstufung	Credit Suisse	Outperform → Neutral
2020-04-01	Fortgesetzt	BofA/Merrill	Buy
2020-03-17	Hochstufung	Citigroup	Neutral → Buy
2020-02-24	Herabstufung	Northland Capital	Outperform → Market Perform
2020-02-14	Herabstufung	Citigroup	Buy → Neutral
2019-09-16	Hochstufung	Goldman	Sell → Neutral
2019-05-29	Herabstufung	Goldman	Neutral → Sell
2019-05-06	Hochstufung	BofA/Merrill	Underperform → Neutral
2019-04-26	Hochstufung	Goldman	Sell → Neutral
2019-03-13	Hochstufung	JP Morgan	Underweight → Neutral
2019-01-07	Bestätigt	Needham	Strong Buy
2018-12-13	Eingeleitet	Goldman	Sell
2018-10-29	Hochstufung	Northland Capital	Market Perform → Outperform
2018-10-16	Eingeleitet	BTIG Research	Buy
2018-08-17	Hochstufung	Citigroup	Neutral → Buy
2018-07-11	Herabstufung	Northland Capital	Outperform → Market Perform
2018-05-03	Herabstufung	JP Morgan	Neutral → Underweight
2018-05-02	Herabstufung	BofA/Merrill	Buy → Underperform

Alle ansehen

Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten

Apr 25, 2025

Esperion Reveals Next-Gen Cholesterol Treatment Strategy: FDA-Approved Non-Statin Leader Updates Growth Plans - Stock Titan

Apr 25, 2025

Esperion to Participate in The Citizens Life Sciences Conference - GlobeNewswire

Apr 25, 2025

Apr 24, 2025

Esperion unveils novel PSC treatment candidates By Investing.com - Investing.com Canada

Apr 24, 2025

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Zacks Investment Research

Apr 24, 2025

Esperion (ESPR) Advances ACLY Inhibitors for Rare Liver Disease Treatment | ESPR Stock News - GuruFocus

Apr 24, 2025

Esperion unveils novel PSC treatment candidates - Investing.com

Apr 24, 2025

Esperion Unveils Promising Research Supporting Lead - GlobeNewswire

Apr 24, 2025

New PSC Liver Disease Treatment Breakthrough: Promising Data Reveals Path to $1B Market Opportunity - Stock Titan

Apr 24, 2025

Apr 23, 2025

Esperion to Report First Quarter 2025 Financial Results on May 6 - The Manila Times

Apr 23, 2025

Esperion Q1 2025 Earnings Preview: What's Next for this FDA-Approved Cardiovascular Drug Maker? - Stock Titan

Apr 23, 2025

Apr 22, 2025

Esperion Therapeutics (ESPR) Loses -51.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

Apr 22, 2025

Apr 21, 2025